

REMARKS

Applicants respectfully request that the above amendment be entered.

Claims 9 and 13 have been cancelled, claims 1, 4 and 10 have been amended, and claims 14-42 have been added. Upon entry of the amendment, claims 1-8, 9-12, and 14-42 will be pending. A marked-up copy of the all the claims showing changes made is attached.

No new matter has been added. Claims 1, 4, and 10 have been amended to clarify and redefine the claimed invention. Support for new claims 14-28 can be found, for example, at the paragraph pages 8 and 9 and at Example 3, pages 14-15. Support for new claims 29-42 can also be found at the paragraph pages 8 and 9 and at Example 3, pages 14-15 as well as at pages 11-13.

Applicants submit that the claims are in condition for allowance and notice to that effect is earnestly solicited. Should the Examiner feel a telephone interview would be helpful in advancing this case to allowance, Applicants invite the Examiner to contact their representative at the number listed below.

Respectfully submitted,

MERCHANT & GOULD P.C.  
P.O. Box 2903  
Minneapolis, Minnesota 55402-0903  
(612) 371-5326

Dated: 02 Jan 2003


By: Keith Campbell  
Keith Campbell  
Reg. No. 46,597

**Version With Markings to Show Changes Made**

Claims 9 and 13 have been canceled.

Claims 1, 4 and 10 have been amended to read as follows.

1. (Amended) A method for ~~treating viral infections comprising extending the elimination half-life of d4T metabolite providing a source of d4T having an extended half-life~~ in a mammal ~~by comprising~~ administering an effective amount of a compound of Formula I:




Formula I

where R<sub>1</sub> is an aryl group substituted with an electron withdrawing group and R<sub>2</sub> is an amino acid residue or an ester of the amino acid residue, or a pharmaceutically acceptable salt thereof.

4. (Amended) The method of claim 1, wherein the electron-withdrawing group is a is halo.

10. (Amended) A method for ~~treating HIV comprising extending the elimination half-life of d4T providing a source of d4T having an extended half-life in a mammal by comprising~~ administering an effective amount of a compound of Formula IV:



Formula IV

where R<sub>2</sub> is an amino acid residue or an ester of the amino acid residue, or a pharmaceutically acceptable salt thereof.

New claims 14 to 44 have been added.